A5027148901- 3D Printing in Biomedical Research
- Pluripotent Stem Cells Research
- Biomedical Ethics and Regulation
- Integrated Energy Systems Optimization
- CRISPR and Genetic Engineering
- Thermodynamic and Exergetic Analyses of Power and Cooling Systems
- Potato Plant Research
- Biomedical and Engineering Education
- Water-Energy-Food Nexus Studies
- Mesenchymal stem cell research
- Landfill Environmental Impact Studies
- Manufacturing Process and Optimization
- Groundwater flow and contamination studies
- Additive Manufacturing and 3D Printing Technologies
- Hybrid Renewable Energy Systems
- Soil Carbon and Nitrogen Dynamics
- Smart Grid Energy Management
- Solar Radiation and Photovoltaics
- Solar Thermal and Photovoltaic Systems
- Crop Yield and Soil Fertility
- Combustion and flame dynamics
- Neuroscience and Neural Engineering
- Plant Disease Resistance and Genetics
- Water resources management and optimization
- Polymer-Based Agricultural Enhancements
National Institute of Technology Srinagar
2023
Loughborough University
2008-2019
Engineering and Physical Sciences Research Council
2014
Indian Institute of Technology Delhi
1986-2006
IBM Research - Austin
2003
Indian Institute of Technology Indore
1988-1989
Use of clinical-grade human induced pluripotent stem cell (iPSC) lines as a starting material for the generation cellular therapeutics requires demonstration comparability derived from different individuals and in facilities. This agreement on critical quality attributes such assays that should be used. Working established recommendations guidance International Stem Cell Banking Initiative embryonic banking, concentrating those issues more relevant to iPSCs, series consensus workshops has...
Tissue engineering scaffolds require a controlled pore size and structure to host tissue formation.Supercritical carbon dioxide (scCO 2 ) processing may be used form foamed in which the escape of CO from plasticized polymer melt generates gas bubbles that shape developing pores.The process forming these involves simultaneous change phase polymer, resulting rapid expansion surface area changes rheological properties.Hence, is difficult control with respect desired final structure.In this...
Large-scale manufacture of human embryonic stem cells (hESCs) is prerequisite to their widespread use in biomedical applications. However, current hESC culture strategies are labor-intensive and employ highly variable processes, presenting challenges for scaled production commercial development. Here we demonstrate that passaging the lines, HUES7, NOTT1, with trypsin feeder-free conditions, compatible complete automation on CompacT SelecT, a commercially available industrially relevant...
Cell culture is one of the critical bioprocessing steps required to generate sufficient human-derived cellular material for most cell-based therapeutic applications in regenerative medicine. Automated cell expansion fundamental development scaled, robust and cost effective commercial production processes products. This paper describes first application process capability analysis establish compare short-term manual automated vitro a selected anchorage-dependent line. Estimates indices (Cp,...
Consistent and robust manufacturing is essential for the translation of cell therapies, utilisation automation throughout process may allow improvements in quality control, scalability, reproducibility economics process. The aim this study was to measure establish comparability between alternative steps culture hiPSCs. Consequently, effects manual centrifugation automated non-centrifugation steps, performed using TAP Biosystems' CompacT SelecT platform, upon a human induced pluripotent stem...
This paper summarizes the proceedings of a workshop held at Trinity Hall, Cambridge to discuss comparability and includes additional information references related added subsequently workshop. Comparability is need demonstrate equivalence product after process change; recent publication states that this 'may be difficult for cell-based medicinal products'. Therefore well-managed change required which needs access good science regulatory advice developers are encouraged seek help early. The...
The translation of experimental cell-based therapies to volume produced commercially successful clinical products that satisfy the regulator requires development automated manufacturing processes achieve capable and scaleable are both economic able meet unpredictable demands market place. Healthcare Engineering group at Loughborough has conducted novel demonstrators transfer manual human cell culture CompacT SelecT (The Automation Partnership) platform, including an osteoblast line,...
Human stem cells have the potential to transform medicine. However, hurdles remain ensure that manufacturing processes produce safe and effective products. A thorough understanding of biological occurring during manufacture is fundamental assuring these qualities thus, their acceptability regulators clinicians. Leaders in both human pluripotent somatic cells, were brought together with experts clinical translation, biomanufacturing regulation, discuss key issues appropriate conditions for...
The concept of applying rapid manufacturing technology to maxillofacial treatment has been described previously; however, these reports did not take into account the practicality its actual incorporation clinical practice. Patents in field are based on imaging techniques combined with manufacturing, which theoretically lead reconstruction faces. Some cases studies reported have dealt manufacture prostheses laboratory scale. Here two case that used and for making an ear prosthesis a burns...
Academic centers, hospitals and small companies, as typical development settings for UK regenerative medicine assets, are significant contributors to the of autologous cell-based therapies. Often lacking appropriate funding, quality assurance heritage or specialist regulatory expertise, qualifying aseptic cell processing facilities GMP compliance is a challenge. The qualification new Cell Therapy Manufacturing Facility with automated capability, first its kind in academic setting, provides...
Human pluripotent stem cells (hPSCs) have the potential to transform medicine. However, hurdles remain ensure safety for such cellular products. Science-based understanding of requirements source materials is required as are appropriate materials. Leaders in hPSC biology, clinical translation, biomanufacturing and regulatory issues were brought together define production hPSC-derived therapies identify other key cell therapy While focus this meeting was on therapies, many generic all...
Automation will likely to play a key role in the development of scalable manufacturing processes for cell-based therapies. In this study, we have compared effects manual centrifugation and automated non-centrifugation cell culture process steps, performed using TAP biosystems' CompacT SelecT platform, upon hMSC morphology, number, viability, surface marker expression, Short tandem repeat (STR) profile, paracrine function. Furthermore, comparability between flow cytometry analyses hMSCs, at...
Establishing how to effectively manufacture cell therapies is an industry-level problem. Decentralised manufacturing of increasing importance, and its challenges are recognised by healthcare regulators with deviations comparability issues receiving specific attention from them. This paper the first report other risks encountered when implementing expansion human pluripotent stem cells (hPSCs) in automated three international site-decentralised setting. An experimental demonstrator project...
Increased global connectivity has catalyzed technological development in almost all industries, part through the facilitation of novel collaborative structures. Notably, open innovation and crowd-sourcing—of expertise and/or funding—has tremendous potential to increase efficiency with which biomedical ecosystems interact deliver safe, efficacious affordable therapies patients. Consequently, such practices offer advancing cellular therapies. In this vein, CASMI Translational Stem Cell...